The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. - Concepedia

Concepedia

Publication | Closed Access

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

39

Citations

0

References

2016

Year

Martin Svatoň, Ondřej Fiala, Miloš Pešek, Zbyněk Bortlíček, Marek Minárik, Lucie Benešová, Ondřej Topolčan

Abstract

The presence of KRAS mutation (especially KRAS G12C mutation) correlated with adverse prognosis in patients treated with second- or third-line pemetrexed or docetaxel.